Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 9/20 | 0.54 |
| ▸ | CA1 | P00915 | 7/20 | 0.46 |
| ▸ | HSD17B2 | P37059 | 3/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | YWHAG | P61981 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31225941 | 1.00 | CA2 (0.54) | CA2CA1HSD17B2SIGMAR1CYP1A2 | |
| SCHEMBL31225825 | 0.89 | SIGMAR1 (0.41) | CA2SIGMAR1CYP1A2CYP2D6TSHR | |
| SCHEMBL22046620 | 0.86 | BACE1 (0.45) | CA2CA1ALDH1A1 | |
| SCHEMBL18790062 | 0.82 | CA2 (0.45) | CA2CA1HSD17B2SIGMAR1CYP1A2 | |
| SCHEMBL31225832 | 0.82 | SIGMAR1 (0.40) | SIGMAR1CYP1A2CYP2D6TSHRALDH1A1 | |
| SCHEMBL499428 | 0.81 | KMT2A (0.46) | TSHRALDH1A1 | |
| SCHEMBL7522573 | 0.81 | TSHR (0.58) | HSD17B2TSHRALDH1A1GAA | |
| SCHEMBL9465229 | 0.80 | MGLL (0.48) | TSHRALDH1A1KDM4E | |
| SCHEMBL13702252 | 0.79 | POLB (0.43) | CA2CA1TSHRALDH1A1KDM4E | |
| SCHEMBL31225767 | 0.79 | P2RX7 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250064941-A1 | SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF | ADAXION THERAPEUTICS, INC. | 2025-02-27 | — | — | US | disclosed |
| US-20190247388-A1 | OLIGOMER-OPIOID AGONIST CONJUGATES | NEKTAR THERAPEUTICS | 2019-08-15 | — | — | US | disclosed |
| US-10307416-B2 | Oligomer-opioid agonist conjugates | NEKTAR THERAPEUTICS (US) | 2019-06-04 | — | — | US | disclosed |
| US-20190046523-A1 | OLIGOMER-OPIOID AGONIST CONJUGATES | NEKTAR THERAPEUTICS | 2019-02-14 | — | — | US | disclosed |
| US-9827239-B2 | Oligomer-opioid agonist conjugates | NEKTAR THERAPEUTICS (US) | 2017-11-28 | — | — | US | disclosed |
| US-9827239-B2 | Oligomer-opioid agonist conjugates | NEKTAR THERAPEUTICS (US) | 2017-11-28 | — | — | US | disclosed |
| EP-3222293-A1 | OLIGOMER-OPIOID AGONIST CONJUGATES | Nektar Therapeutics (US) | 2017-09-27 | — | — | EP | disclosed |
| EP-2620163-B1 | OLIGOMER-OPIOID AGONIST CONJUGATES | NEKTAR THERAPEUTICS (US) | 2017-05-03 | — | — | EP | disclosed |
| US-20170112826-A1 | OLIGOMER-OPIOID AGONIST CONJUGATES | NEKTAR THERAPEUTICS | 2017-04-27 | — | — | US | disclosed |
| US-20170112826-A1 | OLIGOMER-OPIOID AGONIST CONJUGATES | NEKTAR THERAPEUTICS | 2017-04-27 | — | — | US | disclosed |
| US-20120289548-A1 | OLIGOMER-OPIOID AGONIST CONJUGATES | NEKTAR THERAPEUTICS (US) | 2012-11-15 | — | — | US | disclosed |
| US-20120264775-A1 | Oligomer-Opioid Agonist Conjugates | NEKTAR THERAPEUTICS (US) | 2012-10-18 | — | — | US | disclosed |
| US-20120264775-A1 | Oligomer-Opioid Agonist Conjugates | NEKTAR THERAPEUTICS (US) | 2012-10-18 | — | — | US | disclosed |
| US-20120184581-A1 | Oligomer-Opioid Agonist Conjugates | NEKTAR THERAPEUTICS (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120184581-A1 | Oligomer-Opioid Agonist Conjugates | NEKTAR THERAPEUTICS (US) | 2012-07-19 | — | — | US | disclosed |
| US-8173666-B2 | Oligomer-opioid agonist conjugates | NEKTAR THERAPEUTICS (US) | 2012-05-08 | — | — | US | disclosed |
| US-8173666-B2 | Oligomer-opioid agonist conjugates | NEKTAR THERAPEUTICS (US) | 2012-05-08 | — | — | US | disclosed |
| US-20100048602-A1 | Oligomer-Opioid Agonist Conjugates | NEKTAR THERAPEUTICS (US) | 2010-02-25 | — | — | US | disclosed |
| US-20100048602-A1 | Oligomer-Opioid Agonist Conjugates | NEKTAR THERAPEUTICS (US) | 2010-02-25 | — | — | US | disclosed |
| WO-2008112288-A2 | OLIGOMER-OPIOID AGONIST CONJUGATES | NEKTAR THERAPEUTICS (US) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170112826-A1 | OLIGOMER-OPIOID AGONIST CONJUGATES | OPRM1, OPRL1, OPRK1 | CA2 4481/4885CA1 3927/4885HSD17B2 2267/4885 |
| US-10307416-B2 | Oligomer-opioid agonist conjugates | OPRM1, OPRL1, OPRK1 | CA2 4481/4885CA1 3927/4885HSD17B2 2267/4885 |
| US-20190046523-A1 | OLIGOMER-OPIOID AGONIST CONJUGATES | OPRM1, OPRL1, OPRK1 | CA2 4481/4885CA1 3927/4885HSD17B2 2267/4885 |
| US-20190247388-A1 | OLIGOMER-OPIOID AGONIST CONJUGATES | OPRM1, OPRL1, OPRK1 | CA2 4481/4885CA1 3927/4885HSD17B2 2267/4885 |
| US-20250064941-A1 | SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF | SIGLEC7, SIGLEC9, CD2BP2 | CA2 3330/4885CA1 669/4885HSD17B2 4172/4885 |
| US-20120184581-A1 | Oligomer-Opioid Agonist Conjugates | OPRM1, OPRL1, OPRK1 | CA2 4481/4885CA1 3927/4885HSD17B2 2267/4885 |
| US-20100048602-A1 | Oligomer-Opioid Agonist Conjugates | OPRM1, OPRL1, OPRK1 | CA2 4481/4885CA1 3927/4885HSD17B2 2267/4885 |
| US-20120289548-A1 | OLIGOMER-OPIOID AGONIST CONJUGATES | OPRM1, OPRL1, OPRK1 | CA2 4481/4885CA1 3927/4885HSD17B2 2267/4885 |
| US-20120264775-A1 | Oligomer-Opioid Agonist Conjugates | OPRM1, OPRL1, OPRK1 | CA2 4481/4885CA1 3927/4885HSD17B2 2267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.